Reviewing iBio (NASDAQ:IBIO) and Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Valuation and Earnings

This table compares Opus Genetics and iBio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	35.16	-$49.59 million	($1.35)	-4.47
iBio	$100,000.00	774.94	-$33.04 million	($0.34)	-3.54

iBio has lower revenue, but higher earnings than Opus Genetics. Opus Genetics is trading at a lower price-to-earnings ratio than iBio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Opus Genetics and iBio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	15	1	2.89
iBio	1	0	4	3	3.12

Opus Genetics currently has a consensus target price of $11.92, suggesting a potential upside of 97.40%. iBio has a consensus target price of $5.00, suggesting a potential upside of 314.94%. Given iBio’s stronger consensus rating and higher possible upside, analysts plainly believe iBio is more favorable than Opus Genetics.

Profitability

This table compares Opus Genetics and iBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	-338.88%	-150.13%
iBio	N/A	-40.66%	-35.78%

Institutional and Insider Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by insiders. Comparatively, 2.8% of iBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Opus Genetics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, iBio has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Summary

iBio beats Opus Genetics on 11 of the 15 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About iBio

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.